



Universiteit
Leiden
The Netherlands

Cardiac troponins and cardiovascular disease risk prediction an individual-participant-data meta-analysis

Shah, A.S.V.; Keene, S.J.; Pennells, L.; Kaptoge, S.; Kimenai, D.M.; Walker, M.; ... ; CAPRICE Co-Investigators

Citation

Shah, A. S. V., Keene, S. J., Pennells, L., Kaptoge, S., Kimenai, D. M., Walker, M., ... Angelantonio, E. di. (2025). Cardiac troponins and cardiovascular disease risk prediction an individual-participant-data meta-analysis. *Journal Of The American College Of Cardiology*, 85(14), 1471-1484. doi:10.1016/j.jacc.2025.02.016

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4300320>

Note: To cite this publication please use the final published version (if applicable).

ORIGINAL RESEARCH

Cardiac Troponins and Cardiovascular Disease Risk Prediction

An Individual-Participant-Data Meta-Analysis



Anoop S.V. Shah, MPH, MD, PhD,^{a,b,*} Spencer J. Keene, PhD,^{c,d,e,*} Lisa Pennells, PhD,^{c,d} Stephen Kaptoge, PhD,^{c,d} Dorien M. Kimenai, PhD,^f Matthew Walker, PhD,^{c,d} Julianne D. Halley, PhD,^{c,d} Sara Rocha, MSc,^{c,d} Ron C. Hoogeveen, PhD,^g Vilundur Gudnason, MD, PhD,^{h,i} Stephan J.L. Bakker, MD, PhD,^j Sasiwarang G. Wannamethee, PhD,^k Manan Pareek, MD, PhD,^{l,m} Kai M. Eggers, MD, PhD,ⁿ J. Wouter Jukema, MD, PhD,^{o,p} Graeme J. Hankey, MD,^{q,r} James A. deLemos, MD,^s Ian Ford, PhD,^t Torbjørn Omland, MPH, MD, PhD,^{u,v} Magnus Nakrem Lyngbakken, MD, PhD,^{u,v} Bruce M. Psaty, MD, PhD,^w Christopher R. deFilippi, MD,^x Angela M. Wood, PhD,^{c,d,e,y,z,aa,bb} John Danesh, MD, PhD,^{c,d,e,y,z,cc} Paul Welsh, PhD,^{dd,†} Naveed Sattar, MChB, PhD,^{dd,†} Nicholas L. Mills, MD, PhD,^{f,ee,†} Emanuele Di Angelantonio, MD, MSc, PhD,^{c,d,e,y,z,ff,†} the CAPRICE Co-Investigators

ABSTRACT

BACKGROUND The extent to which high-sensitivity cardiac troponin can predict cardiovascular disease (CVD) is uncertain.

OBJECTIVES We aimed to quantify the potential advantage of adding information on cardiac troponins to conventional risk factors in the prevention of CVD.

METHODS We meta-analyzed individual-participant data from 15 cohorts, comprising 62,150 participants without prior CVD. We calculated HRs, measures of risk discrimination, and reclassification after adding cardiac troponin T (cTnT) or I (cTnI) to conventional risk factors. The primary outcome was first-onset CVD (ie, coronary heart disease or stroke). We then modeled the implications of initiating statin therapy using incidence rates from 2.1 million individuals from the United Kingdom.

RESULTS Among participants with cTnT or cTnI measurements, 8,133 and 3,749 incident CVD events occurred during a median follow-up of 11.8 and 9.8 years, respectively. HRs for CVD per 1-SD higher concentration were 1.31 (95% CI: 1.25-1.37) for cTnT and 1.26 (95% CI: 1.19-1.33) for cTnI. Addition of cTnT or cTnI to conventional risk factors was associated with C-index increases of 0.015 (95% CI: 0.012-0.018) and 0.012 (95% CI: 0.009-0.015) and continuous net reclassification improvements of 6% and 5% in cases and 22% and 17% in noncases. One additional CVD event would be prevented for every 408 and 473 individuals screened based on statin therapy in those whose CVD risk is reclassified from intermediate to high risk after cTnT or cTnI measurement, respectively.

CONCLUSIONS Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale. (JACC. 2025;85:1471-1484)

© 2025 by the American College of Cardiology Foundation.



Listen to this manuscript's audio summary by Editor Emeritus Dr Valentin Fuster on www.jacc.org/journal/jacc.

From the ^aDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; ^bDepartment of Cardiology, Imperial College NHS Trust, London, United Kingdom; ^cBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ^dVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom; ^eNational Institute for Health and Care Research Blood and Transplant Research Unit in Donor Health and Behaviour, University of

**ABBREVIATIONS
AND ACRONYMS**

CHD = coronary heart disease

CRP = C-reactive protein

cTnl = cardiac troponin I

cTnT = cardiac troponin T

CVD = cardiovascular disease

eGFR = estimated glomerular
filtration rate

ESC = European Society of
Cardiology

HDL-C = high-density
lipoprotein cholesterol

NT-proBNP = N-terminal
pro-B-type natriuretic peptide

Guidelines recommend measurement of cardiac troponins—structural proteins released into the circulation following myocardial injury—for the assessment of patients with suspected acute coronary syndrome, during which circulating troponins are significantly elevated.¹⁻⁵ However, because assays for cardiac troponins (including cardiac troponin T [cTnT] and troponin I [cTnI]) are now highly sensitive and specific, they can quantify even very low circulating concentrations among apparently healthy individuals.^{6,7}

SEE PAGE 1485

A key strategy in the prevention of cardiovascular disease (CVD) is the use of risk prediction algorithms that integrate conventional risk factors to identify individuals who could benefit most from preventive interventions, such as statin therapy.⁸⁻¹⁰ Current clinical guidelines also recommend incorporating additional biomarkers when an individual's risk level does not meet a clear decision threshold, providing opportunities for enhanced risk stratification.^{9,10} However, the population health utility of cardiac injury biomarkers such as troponins in improving CVD risk prediction remains uncertain.⁸ Previous studies have focused only on measures of risk discrimination and recalibration but lacked

modeling of the clinical implications of initiating guideline-recommended interventions (eg, statin therapy).^{6,7,11,12} This limitation has hindered the evaluation of the potential clinical benefits of routinely measuring cardiac troponins in apparently healthy individuals for the prevention of CVD.

To address these gaps, our study aimed to answer 2 key questions. First, what is the improvement in CVD risk prediction when cardiac troponins are added to risk factors used in conventional risk algorithms? We analyzed data from 62,150 participants in 15 prospective longitudinal general population cohorts to assess the value of adding cardiac troponins to several conventional risk factors. Second, what is the estimated population health impact of incorporating cardiac troponins into CVD risk assessment? Using data from 2.1 million individuals in the UK CPRD (Clinical Practice Research Datalink),¹³ we modeled the potential clinical benefit of initiating statin therapy in accordance with current guidelines.⁸⁻¹⁰ To contextualize our findings, we compared the incremental predictive gains afforded by cardiac troponins with those provided by C-reactive protein (CRP), a plasma biomarker recommended for risk prediction in some CVD primary prevention guidelines,^{9,10} estimated glomerular filtration rate (eGFR), a biomarker of kidney function that estimates how well the kidneys filter waste and excess fluid from the

Cambridge, Cambridge, United Kingdom; [†]British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; [‡]Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; [§]Icelandic Heart Association, Kopavogur, Iceland; ^{||}Faculty of Medicine, University of Iceland, Reykjavik, Iceland; [¶]Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ^{‡‡}Department of Primary Care and Population Health, UCL, London, United Kingdom; ^{††}Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ^{‡‡‡}Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; ^{‡‡‡‡}Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ^{‡‡‡‡‡}Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; ^{‡‡‡‡‡‡}Netherlands Heart Institute, Utrecht, the Netherlands; ^{‡‡‡‡‡‡‡}Centre for Neuromuscular and Neurological Diseases, The University of Western Australia, Perth, Western Australia, Australia; ^{‡‡‡‡‡‡‡‡}Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia; ^{‡‡‡‡‡‡‡‡‡}UT Southwestern Medical Center, Cardiology, Dallas, Texas, USA; ^{‡‡‡‡‡‡‡‡‡‡}Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡}K. G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ^{‡‡‡‡‡‡‡‡‡‡‡‡}Department of Cardiology, Akershus University Hospital, Lørenskog, Norway; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡}Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Systems and Population Health, University of Washington, Seattle, Washington, USA; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Inova Schar Heart and Vascular, Falls Church, Virginia, USA; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Cambridge Centre of Artificial Intelligence in Medicine, Cambridge, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}British Heart Foundation Data Science Centre, Health Data Research UK, London, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Department of Human Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; and the ^{‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡}Health Data Science Research Centre, Human Technopole, Milan, Italy. *These authors contributed equally to this work and are joint primary authors. †These authors contributed equally to this work and are joint senior authors.

The views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

blood,¹⁴ and N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of neurohormonal activation that could also serve as an adjunct in the prediction of first-onset CVD.¹⁵

METHODS

DATA SOURCES. To evaluate the role of cardiac troponins in the primary prevention of CVD, we established the CAPRICE (CARDiac troponin in the PRevention of Cardiovascular Events) collaboration, an international consortium of longitudinal cohort studies including individuals without a history of CVD at baseline that agreed to share individual-participant data. Details of the initial search strategy and methods used to collect and harmonize data are detailed in [Supplemental Text 1](#). Studies were eligible if they had: 1) assayed cTnT^{5,16-26} or cTnI^{21,22,25,27-29} using a high-sensitivity assay;^{5,30} 2) recorded baseline information on age, sex, smoking status (current vs other [former and never]), history of diabetes, systolic blood pressure, total and high-density lipoprotein cholesterol concentration (henceforth, “conventional risk factors”); 3) included participants without a known history of CVD (ie, coronary heart disease [CHD], stroke, transient ischemic attack, peripheral vascular disease, or cardiovascular surgery) at entry into the study; and 4) recorded cause-specific deaths and major cardiovascular morbidity (nonfatal myocardial infarction or stroke) over at least 1 year of follow-up.

Contributing studies classified deaths according to the primary cause (or, in its absence, the underlying cause) based on International Classification of Diseases coding, revisions 8 to 10, to at least 3 digits, or according to study-specific classification systems. We based ascertainment of fatal outcomes on death certificates, supplemented in 10 cohorts by additional data, and of nonfatal outcomes on World Health Organization (or similar) criteria for myocardial infarction and for stroke ([Supplemental Table 1](#)). The Newcastle-Ottawa scale was used to assess the quality of the included cohorts ([Supplemental Table 2](#)).³¹ This study followed the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) reporting guidelines ([Supplemental Text 2](#)).³²

To estimate the potential for disease prevention in a general population setting, we used data from the CPRD, a primary care database of anonymized medical records covering >20 million individuals opting into data linkage from more than 675 general practices in the United Kingdom.¹³ Individual-level data from consenting practices in the CPRD have been

linked to hospital episode statistics (HES) and the national death registry. Details of the CPRD data used and endpoint definition are provided in [Supplemental Text 1](#). The present analysis involved records of 2.1 million patients, a random sample of all CPRD data, working under the assumption that individuals in this database should be broadly representative of the UK general population.

The study was conducted by the CAPRICE independent coordinating center at the University of Cambridge and the London School of Hygiene and Tropical Medicine. All cohorts were approved by the Institutional Review Boards of the participating institutions with participants providing written informed consent. The current study proposal was reviewed and approved by the Research Ethics Committee at the University of Cambridge.

DATA ANALYSIS. The analysis involved 4 interrelated components. First, we characterized cross-sectional associations of cardiac troponin concentrations with established and emerging risk factors. Second, we assessed associations of cardiac troponin concentrations with subsequent risk of first-onset CHD (defined as fatal or nonfatal myocardial infarction) and stroke, considering these outcomes alone and in combination. Third, we quantified the incremental value of information on cardiac troponin concentrations, beyond that of conventional risk factors, for predicting major CVD outcomes. Fourth, we assessed the population health relevance of adding cardiac troponins to conventional risk factors, by generalizing our analyses to the context of a UK population eligible for CVD risk assessment.

The primary outcome was a first-onset CVD event defined as the composite of any fatal or nonfatal CHD or any stroke.³³ Secondary outcomes included CHD and stroke separately. Participants contributed only the first CVD outcome (whether nonfatal or fatal) recorded during follow-up (ie, we did not include deaths preceded by nonfatal CVD events). We censored outcomes if a participant was lost to follow-up, died from causes other than CVD, or reached the end of the follow-up period. Individuals with cTnT or cTnI values at or below the limit of detection (3.00 ng/L for cTnT or 1.20 ng/L for cTnI) were assigned a value of 2.99 ng/L for cTnT or 1.19 ng/L for cTnI.^{21,22} All continuous analyses were based on log-transformed cTnT and cTnI concentrations.

Cross-sectional correlates were estimated using linear fixed-effects regression of cTnT and cTnI on quintiles of continuous variables and categorical variables adjusted for age and sex.³⁴ To evaluate associations between cTnT and cTnI with primary and

TABLE 1 Baseline Characteristics of Participants From Cohorts With Measured Cardiac Troponin T or Troponin I


	Participants With Assessment of Cardiac Troponin T	Participants With Assessment of Cardiac Troponin I
Baseline characteristics		
Participants	50,523	28,090
Cohorts	11	6
Age, y	61 ± 11	60 ± 12
Female	26,292 (52)	13,881 (49)
Cardiovascular risk factors		
Current smoker	9,735 (19)	5,461 (20)
History of diabetes	4,154 (8)	1,317 (5)
Body mass index, kg/m ²	27.4 ± 5.0	26.9 ± 4.5
Systolic blood pressure, mm Hg	134 ± 22	139 ± 20
Total cholesterol, mmol/L	5.47 ± 1.09	5.76 ± 1.13
HDL cholesterol, mmol/L	1.41 ± 0.42	1.46 ± 0.42
Biomarkers of cardiac injury, inflammation, and renal function		
Cardiac troponin T, ng/L	5.0 (3.0-9.0)	-
Cardiac troponin I, ng/L	-	3.3 (2.1-5.2)
NT-proBNP, ng/mL	63 (33-121)	51 (26-94)
C-reactive protein, mg/L	1.89 (0.89-4.00)	1.50 (0.70-3.20)
Creatinine, μmol/l	81 (71-97)	81 (70-93)
Primary outcomes		
CVD cases	8,133	3,749
Follow-up, y	11.80 (8.67-17.74)	9.75 (8.25-12.42)
<small>Values are n, mean ± SD, n (%), or median (Q1-Q3). Table shows information on all individuals, regardless of missing values in covariates included in subsequent regression models. Subsequent tables and figures are based on a complete-case analysis. CVD = cardiovascular disease; NT-proBNP = N-terminal pro-B-type natriuretic peptide.</small>		

secondary outcomes, HRs were calculated separately within each study using Cox proportional hazards regression models stratified by sex, using time-on-study as the timescale. The proportional hazards assumption was assessed using Schoenfeld residuals. HRs were adjusted for conventional risk factors (age, sex, smoking status, systolic blood pressure, history of diabetes, and total and high-density lipoprotein cholesterol [HDL-C] concentrations) and pooled across cohorts using multivariate random-effects meta-analysis.³⁵ We investigated effect modification by individual characteristics with formal tests of interaction.³⁵ To characterize shapes of associations, we calculated pooled HRs within overall fifths of cardiac troponin concentrations and plotted them against the pooled geometric mean of cardiac troponins concentration within each fifth. Additional analyses used martingale residuals, fractional polynomials, restricted maximum likelihood models, and Fine and Gray³⁶ competing risk-adjusted models.

We used CVD risk prediction models containing information about conventional risk factors first without and then with cardiac troponins. We quantified improvements in predictive ability using

measures of risk discrimination and reclassification.^{37,38} We calculated Harrell's C-indices and C-index changes within each study before pooling results weighted by the number of outcomes contributed. To avoid overestimation of the model's ability to predict risk, we applied a cross-validation approach (by leaving 1 cohort out).³⁹ We examined the change in C-index after adding cardiac troponins and other circulating biomarkers as both linear and quadratic terms. We calculated the continuous net reclassification improvement using data from studies in which both fatal and nonfatal CVD events had been recorded and separately among stroke and CHD cases and noncases.

To assess the population health relevance of adding cardiac troponins to conventional risk factors, we generalized our reclassification analyses to the context of a UK population eligible for CVD risk assessment ([Supplemental Text 1](#)). Using incidence rates calculated from CPRD data, we recalibrated the risk prediction models from our analysis to give 10-year risks that would be expected in a UK primary care setting, using methods previously described.⁴⁰ We modeled a population of 100,000 adults aged 40 to 89 years in CPRD, with an age and sex structure matching that of the UK general population, and CVD incidence rates observed among individuals without previous CVD or diabetes, and not taking statins.⁴¹ We then modeled the population health impact of additional assessment of troponin for individuals at intermediate 10-year CVD risk based on conventional risk factors alone. The intermediate-risk group was defined according to the European Society of Cardiology (ESC) 2021 guidelines as a risk of 2.5% to <7.5% in those aged <50 years old, 5% to <10% in those aged 50 to <69 years old, and 7.5% to 15% in those aged 70 years or older.⁸ We also modeled the potential population health impact for the intermediate-risk group defined by the National Institute for Health and Care Excellence guidelines.⁴¹ Assuming a policy of statin allocation for people in the highest 10-year risk category, we estimated the potential that treatment allocation would result in a proportional reduction of ~20% in CVD risk across different individual-level characteristics.⁴² Additional analyses assumed larger reductions in risk with statin treatment. The number needed to screen to prevent 1 CVD event was quantified from this modeling procedure and included 95% CIs calculated using 200 bootstrap standard errors. Findings are based on complete case analysis. Stata/SE version 17 was used for all analyses, with 2-sided P values and 95% CIs.



RESULTS

BASELINE CHARACTERISTICS AND ASSOCIATION WITH CVD OUTCOMES. Individual participant data were available on 62,150 participants without a history of CVD from 15 prospective studies. A total of 30,144 (48.5%) participants were women and the mean age was 61 ± 12 years. Most participants were enrolled in either Europe (65%) or North America (33%). cTnT was measured in 50,523 participants from 11 studies,^{6,16-26} cTnI in 28,090 participants from 6 studies,^{21,22,25,27-29} and 2 studies measured both.^{21,25,43} Across all cohorts, cardiac troponin was measured using either the Elecsys Troponin T high-sensitive (Roche Diagnostics) or ARCHITECT_{STAT} high-sensitivity troponin I (Abbott Diagnostics) assays.⁴⁴ Median concentrations were 5.0 ng/L (Q1-Q3: 3.0-9.0) and 3.3 ng/L (Q1-Q3: 2.1-5.2) for cTnT and cTnI, respectively. Details of the contributing studies are provided in [Table 1](#), [Supplemental Tables 3 and 4](#), and [Supplemental Figure 1](#).^{6,16-29} cTnT and cTnI concentrations increased with age and were lower in women, but were only weakly associated with several

other characteristics, including history of diabetes, systolic and diastolic blood pressure, body mass index, total and HDL-C concentration, and creatinine ([Supplemental Figures 2 to 4](#)).

Among participants with an assessment of cTnT or cTnI, the median follow-up was 11.8 years (Q1-Q3: 8.7-17.7 years) and 9.8 years (Q1-Q3: 8.3-12.4 years), during which 8,133 and 3,749 incident CVD events occurred, respectively ([Table 1](#), [Supplemental Tables 3 and 4](#)). cTnT and cTnI concentrations were approximately linearly associated with CVD risk ([Figure 1](#), [Supplemental Figure 5](#)). HR for the composite CVD outcome (per 1 SD higher log-transformed concentration) adjusted for conventional risk factors were 1.31 (95% CI: 1.25-1.37) and 1.26 (95% CI: 1.19-1.33) for cTnT and cTnI, respectively ([Figure 2](#), [Supplemental Figures 6 and 7](#)). Corresponding HRs for NT-proBNP, eGFR, and CRP for the composite CVD outcomes were 1.37 (95% CI: 1.30-1.44), 1.12 (95% CI: 1.02-1.22), and 1.16 (95% CI: 1.12-1.20), respectively ([Figure 2](#), [Supplemental Figures 8 and 9](#)). HRs were similar for CHD and stroke outcomes, but slightly higher for fatal CVD outcomes ([Figure 3](#)). HRs were somewhat higher

FIGURE 2 Adjusted HRs of Conventional Cardiovascular Risk Factors and Biomarkers for Comparison With Cardiac Troponin T and Cardiac Troponin I

	Cohorts/Participants/Events		HR (95% CI)	P Value
Conventional Risk Factors				
Age, Per 5 Years	15/60,915/9,906		1.49 (1.40-1.58)	<0.001
Current Smoker	15/60,916/9,907		1.59 (1.43-1.77)	<0.001
History of Diabetes	15/60,916/9,907		1.67 (1.48-1.88)	<0.001
Systolic Blood Pressure, mm Hg	15/60,914/9,906		1.29 (1.22-1.36)	<0.001
Total Cholesterol, mmol/L	15/60,915/9,906		1.10 (1.06-1.15)	<0.001
High-Density Lipoprotein Cholesterol, mmol/L	15/60,915/9,906		1.15 (1.10-1.19)	<0.001
Circulating Cardiac-Related Biomarkers				
C-Reactive Protein, mg/L	13/39,825/7,037		1.16 (1.12-1.20)	<0.001
N-Terminal Pro B-Type Natriuretic Peptide, pg/mL	10/31,838/3,948		1.37 (1.30-1.44)	<0.001
eGFR, mL/min/1.73 m ²	9/27,184/3,869		1.12 (1.02-1.22)	0.012
Troponin-T, ng/L	11/49,405/7,966		1.31 (1.25-1.37)	<0.001
Troponin-I, ng/L	6/27,384/3,634		1.26 (1.19-1.33)	<0.001

HRs were estimated using Cox regression, stratified by cohort and sex, and adjusted for age at baseline, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol levels, where appropriate. For categorical variables, HRs are shown for patients with diabetes vs without, and for current smokers vs others. For continuous variables, HRs are shown per SD higher of each predictor to facilitate comparison, except age. For high-density lipoprotein cholesterol and estimated glomerular filtration rate (eGFR), the HR is shown per SD lower. The SD for the continuous variables are systolic blood pressure = 21.6, total cholesterol = 1.11, high-density lipoprotein = 0.42, natural log (ln) of C-reactive protein = 1.18, ln of N-terminal pro-B-type natriuretic peptide = 1.13, ln of cardiac troponin T = 0.68, ln of cardiac troponin I = 0.85, and eGFR = 16.2.

for female compared with male individuals but did not vary substantially with levels of other conventional risk factors or in other clinically relevant subgroups (Supplemental Figures 10 and 11). Similar results were found using competing risk-adjusted models and meta-analysis using restricted maximum likelihood method (Supplemental Figures 12 and 13).


INCREMENTAL VALUE IN RISK PREDICTION. We assessed the incremental predictive ability of cardiac troponins using measures of risk discrimination and reclassification, adding cTnT or cTnI to models containing conventional CVD risk factors. For incident CVD, the C-index increased by 0.015 (95% CI: 0.012-0.018), from 0.673 (95% CI: 0.667-0.679) to 0.688 (95% CI: 0.682-0.691) for cTnT, and by 0.012 (95% CI: 0.009-0.015), from 0.715 (95% CI: 0.706-0.723) to 0.727 (95% CI: 0.718-0.735) for cTnI (Figure 4). Similar results were observed using cross-validation analyses (Supplemental Figure 14). Continuous net reclassification index values were 6% (95% CI: 3%-9%) among CVD cases and 22% (95% CI: 20%-23%) among noncases for cTnT, and 5% (95% CI: 2%-9%) among CVD cases and 17% (95% CI: 15%-18%) among noncases for cTnI (Table 2, Supplemental Figure 15). Supplemental

Table 5 shows the continuous net reclassification index among stroke and CHD cases and noncases.

Incremental risk prediction demonstrated by cardiac troponins was similar to that of NT-proBNP but greater than CRP and eGFR (Figure 4, Supplemental Figures 16 and 17). The addition of cardiac troponins to CRP demonstrated incremental risk discrimination when compared to adding cardiac troponin alone. In contrast, the addition of cardiac troponins to NT-proBNP or eGFR did not substantially improve risk discrimination, with overlapping CIs. Improvements in C-index with information on cardiac troponin concentrations were possibly greater among older individuals and people with a history of diabetes (Supplemental Figures 18 and 19). Models including cardiac troponins showed good calibration, with good agreement between the observed and predicted CVD risks (Supplemental Figure 20).

ESTIMATE FOR THE POTENTIAL OF DISEASE PREVENTION. For cTnT, and using a conventional cardiovascular risk factor model alone, 35,675 (36%) of 100,000 individuals would be classified as having intermediate 10-year risk according to the 2021 ESC Prevention Guidelines who were not already taking or

FIGURE 3 Associations of Cardiac Troponin T and Cardiac Troponin I Concentrations With Several Incident First-Onset Cardiovascular Outcomes




HRs adjusted for age, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol and stratified by sex and cohort. Cardiac troponin values were (natural) log-transformed (ln) and left as continuous values. HRs represent 1-SD higher ln cardiac troponin value. Error bars are 95% CIs and box sizes are unweighted. Individuals only needed at least 1 component outcome to be defined as a case for the composite outcome. The SD is 0.68 for ln of cardiac troponin T and 0.85 for ln of cardiac troponin I.

eligible for statin treatment (ie, people without a history of diabetes or CVD) (Figure 5). Assessment of cTnT in these individuals (ie, a “targeted” approach focusing only on people judged to be at intermediate 10-year risk of CVD after initial screening with conventional risk factors alone) would re-classify 2,754 intermediate-risk individuals as high risk, of whom approximately 437 (16%) would be expected to have a CVD event within 10 years. This would correspond to an increase of about 4.6% (437 of 9,487) of the CVD events already classified at high risk using conventional risk predictors alone.

Assuming statin allocation as per current ESC guidelines and statin treatment conferring a 20% relative risk reduction,^{42,45} such targeted assessment

of cTnT among the intermediate-risk group would help prevent 87 events over the next 10-year period, equating to the screening of 408 participants to prevent 1 event (Central Illustration). Similar findings were observed with the targeted assessment of cTnI, with 473 participants needing to be screened to prevent 1 event (Figure 5), and when analysis involved cutoffs for clinical risk categories defined by National Institute for Health and Care Excellence guidelines (Supplemental Table 6). For comparison, the numbers needed to screen to prevent 1 event with targeted assessment of NT-proBNP and CRP would be 468 and 593, respectively (Supplemental Table 7). Assuming a larger relative risk reduction from statin treatment of 30% or 40%,⁴⁶ the numbers needed to screen to

FIGURE 4 Improvement in Risk Discrimination for First-Onset Fatal or Nonfatal Cardiovascular Disease by Addition of Information About Cardiac Troponin T and Cardiac Troponin I Concentration Compared With That About HDL-C and Total Cholesterol, CRP, or NT-proBNP Concentration



Cardiac troponin, C-reactive protein (CRP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) values were all (natural) log-transformed. The change in C-index is in reference to the model that included information about age, smoking status, systolic blood pressure, history of diabetes, high-density lipoprotein cholesterol (HDL-C), and concentration of total cholesterol, where relevant. Note that the reference model has a higher C-index for the studies measuring cardiac troponin I compared with cardiac troponin T. **P < 0.01, and ***P < 0.001.

TABLE 2 Continuous Net Reclassification Index and 95% CI for 10-year Fatal or Nonfatal Cardiovascular Disease (Generalized to a Primary Prevention Population)

Conventional risk factors plus cardiac troponin T	
No. of cohorts/participants/events	11/49,405/7,966
Noncases	22 (20-23)
Cases	6 (3-9)
Conventional risk factors plus cardiac troponin I	
No. of cohorts/participants/events	6/27,384/3,634
Noncases	17 (15-18)
Cases	5 (2-9)
Conventional risk factors plus CRP	
No. of cohorts/participants/events	14/39,826/7,037
Noncases	19 (17-20)
Cases	-2 (-5 to 1)
Conventional risk factors plus NT-proBNP	
No. of cohorts/participants/events	11/31,836/3,948
Noncases	21 (19-23)
Cases	-5 (-8 to 0)

Conventional risk factors included age at baseline, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein. Net reclassification index is expressed as a percentage. Cox models were performed by cohort and sex.


CRP = C-reactive protein; NT-proBNP = N-terminal pro-B-type natriuretic peptide; other abbreviation as in Table 1.

prevent 1 event with targeted assessment of cTnT or cTnI would be between 205 and 273 and 237 and 316, respectively (Supplemental Table 8).


DISCUSSION

In an analysis comprising individual participant data on >60,000 participants from 15 prospective cohort studies, we studied the potential value of adding information on cardiac troponins to conventional cardiovascular risk factors used to predict first-onset CVD risk. We then modeled a scenario using CVD incidence rates derived from data from 2.1 million people from general practices in the United Kingdom, in which cardiac troponins were assessed in people considered to be at intermediate risk by current prevention guidelines after initial screening using conventional risk factors alone. Overall, our results suggest that the addition of cardiac troponins to conventional risk factors can provide a modest improvement in the prediction of first-onset CVD, which, if applied at scale, could help detect up to 5% more CVD events than the use of conventional risk

FIGURE 5 Estimated Population Health Impact With Targeted Assessment of Cardiac Troponin T or Cardiac Troponin I Among 100,000 UK Adults in a Primary Care Setting Using Thresholds From European Society of Cardiology 2021 Guidelines



Reclassification analyses was contextualized to a UK population eligible for cardiovascular disease screening that did not include people with a history of diabetes. Those with a history of diabetes were excluded from the calculations of screening benefit because people with diabetes are eligible for statin treatments irrespective of baseline risk. The conventional risk factors model included baseline age, smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein.

CENTRAL ILLUSTRATION Cardiac Troponin in the Prevention of Cardiovascular Events (CAPRICE): A Collaborative Individual Patient Data Meta-Analysis

Shah ASV, et al. JACC. 2025;85(14):1471-1484.

factors alone. Our results have potential implications for CVD risk prediction and for the evaluation of the population health utility of cardiac troponins.

First, our modeling suggests that, if applied to the standard UK general population aged 40 to 89 years, additional use of cardiac troponins could help detect and prevent more CVD events over the next 10 years beyond the assessment of conventional risk factors alone. In a modeled scenario in which cardiac troponins were assessed in a primary care setting among individuals considered at intermediate CVD risk after initial screening with conventional risk predictors alone, our data suggest 1 extra CVD outcome could be prevented over a period of 10 years for approximately every 400 people in whom cardiac troponins are assessed provided this is coupled with initiation of statin therapy in accordance with current guidelines.⁸

Second, to provide clinical context, we compared the incremental predictive gains afforded by information on cardiac troponins with those provided by CRP, eGFR, and NT-proBNP. Our results demonstrated that cardiac troponins provided a greater gain in predictive accuracy compared with CRP and eGFR, whereas NT-proBNP yielded similar results. Although cardiac troponins potentially offered additional improvements in risk discrimination beyond those provided by CRP—suggesting these biomarkers might capture distinct aspects of CVD risk—the improvements from cardiac troponins and NT-proBNP were not additive. This suggests that cardiac troponins and NT-proBNP provide somewhat overlapping information about myocardial damage in the context of primary prevention. We also found that improvements in risk discrimination with cardiac troponins were

greater than those provided by total cholesterol and HDL-C, even though our evaluation was skewed in favor of lipid measurements since we added total cholesterol and HDL-C only to other conventional risk factors (and omitted cardiac troponins), whereas we added cardiac troponins to all conventional risk factors, including total cholesterol and HDL-C. We restricted comparisons of cardiac troponins with other circulating biomarkers to participants who had complete information on these measurements, thereby avoiding potential bias.

Third, we found that cTnT and cTnI provide similar predictive information for CVD risk prediction, indicating that either biomarker can be effectively utilized in clinical settings for the assessment of first-onset CVD risk. This equivalence in predictive ability suggests that the choice between cTnT and cTnI can be flexible, depending on availability and specific clinical scenarios. Our findings align with previous studies that have demonstrated comparable diagnostic and prognostic capabilities of these biomarkers in various populations and clinical conditions.^{3,7,47}

Fourth, our main model assumed that information on cardiac troponins would provide similar predictions of CVD risk across population subgroups. However, an exploratory analysis suggested that these biomarkers could provide more accurate risk prediction in older individuals and in those with a history of diabetes. These findings require cautious interpretation because they could arise, at least to some extent, due to the play of chance from the conduct of multiple statistical tests (because we explored interactions of cardiac troponins with several characteristics). Nevertheless, the potential for more accurate risk prediction in these subgroups raises the possibility that subclinical CVD may be more prevalent among these individuals,⁴⁸ warranting further investigation to determine whether targeting the assessment of cardiac troponins in older individuals and in those with diabetes enhances screening efficiency.

STUDY STRENGTHS AND LIMITATIONS. Our study had major strengths. In all cohorts, cardiac troponin concentrations were measured using commonly used diagnostic assays, with potential for clinical use. We recorded information about the incidence of various CVD outcomes using well-validated endpoint definitions. We centrally analyzed individual-participant data, which were harmonized from prospective studies with extended follow-up, enabling time-to-event analyses, exclusion of people with a baseline history of CVD, and adoption of a uniform approach to statistical analyses. Because of its considerable

statistical power, we could provide precise estimates, even for analyses that involved categorization of cardiac troponin concentrations. To enhance validity further, we restricted analyses to people with complete information about a set of relevant risk factors. We used multiple complementary metrics of risk discrimination and reclassification, as well as different absolute risk thresholds used in different clinical guidelines. The broadly concordant results we observed across these metrics support the validity of our main conclusions. To extend the relevance of our findings to a primary care population, we also conducted modeling using the UK CPRD, adapting (recalibrating) our findings to be more representative of the general population. The generalizability of our findings was enhanced by the inclusion of data from 10 countries and by the robustness of results to various sensitivity analyses.

Our study had some potential limitations. We used a convenience sample of cohorts derived primarily from middle- to older-aged individuals of European continental ancestry, which may limit the generalizability of our findings to other populations. Only 2 contributing cohorts measured both cTnT and cTnI, preventing a reliable head-to-head comparison of cardiac troponins.^{21,25,43} We used a conventional 10-year timeframe and standard clinical risk categories, acknowledging that reclassification analyses are intrinsically sensitive to choices of follow-up interval and clinical risk categories. A somewhat greater population health impact than suggested by our main analysis would be estimated if we had used less conservative modeling assumptions (eg, more effective statin regimens, additional CVD-lowering medications, for example antihypertensives, and longer time horizons). Conversely, our models could have overestimated the potential benefits of assessing cardiac troponins because not all people eligible for statins will receive them, be willing to take them, or adhere to treatment. In addition, if competing risks are not adequately accounted for, population health benefits could be overestimated.³⁶ Data were unavailable to assess the added value of incorporating cardiac troponin measurements into the risk prediction tools currently recommended by US and UK guidelines (ie, QRISK³⁴⁹ and PREVENT [Predicting Risk of cardiovascular disease EVENTS]⁵⁰), as well as when using additional risk modifiers such as coronary calcium scores or polygenic risk scores.⁵¹ Finally, a comprehensive health economic evaluation or an analysis of the feasibility of widespread troponin screening were beyond the scope of the present study.

CONCLUSIONS

We conclude that measurement of cardiac troponin in addition to conventional risk factors results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.

ACKNOWLEDGMENTS Co-Investigators of the CAPRICE Studies Collaboration: AGES-Reyjavik: Ingunn Thorsteinsdottir, Elias F. Gudmundsson, Lenore J. Launer, Vilmundur Gudnason. ARIC: Vijay Nambi, Christie M. Ballantyne, Xiaoming Jia, Ron C. Hoogeveen. BRHS: Peter H. Whincup, Sasiwarang G. Wannamethee. CHS: Bruce Psaty, Stephen Seliger, Jorge R. Kizer, Christopher R. deFilippi. DHS: Colby Ayers, Rebecca Vigen, James A. deLemos. Generation Scotland: Archie Campbell, Caroline Hayward, Catherine Sudlow, Anoop S.V. Shah. HIMS: Osvaldo P. Almeida, Damon A. Bell, Leon Flicker, Graeme J. Hankey. HUNT: Torbjørn Omland, Magnus Lyngbakken. MESA: Christopher R. DeFilippi, Stephen Seliger. MPP-RES: Michael H. Olsen, Peter M. Nilsson, Deepak L. Bhatt, Manan Pareek. PIVUS/ULSAM: Björn Zethelius, Lars Lind, Kai M. Eggers. PREVENT: Stephan J.L. Bakker, Lyanne M. Kieneker, Ronald T. Gansevoort. PROSPER: Ian Ford, Naveed Sattar, Stella Trompet, J. Wouter Jukema. WOSCOPS: Ian Ford. Other: Pablo Perel, Kuan Ken Lee, David A. McAllister. This Cardiovascular Health Study research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006; and NHLBI grants U01HL080295, R01HL087652, R01HL103612, R01HL105756, R01HL120393, U01HL130114, and R01HL172803 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This work was funded by the BHF Intermediate Clinical Fellowship (FS/19/17/34172) held by Dr Shah. The work of the coordinating center was funded by the British Heart Foundation (RG/18/13/33946: RG/F/23/110103), NIHR Cambridge Biomedical Research Centre (NIHR203312), BHF Chair Award (CH/12/2/29428), Cambridge BHF Centre of Research Excellence (RE/24/130011, RE/18/1/34212), and by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and the Wellcome Trust. Dr Mills is supported by a Research Excellence Award (RE/24/130012), Programme Grant (RG/20/10/34966) and Chair Award (CH/F/21/90010) from the British Heart Foundation. [Supplemental Text 3](#) lists some of the funders of the component studies in this analysis provided by investigators. Dr Mills has received honoraria from Abbott Diagnostics, Siemens Healthineers, and Roche Diagnostics over the past 3 years. Dr Sattar has received consulting fees and/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and has received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. Dr Kimenai is supported by a British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/23/25161); and has received honoraria from Roche Diagnostics outside the submitted work. Dr Omland has received research support via institution from Abbott Laboratories, CardiNor, ChromaDex, Novartis, and Roche Diagnostics; and has received honoraria from Abbott Laboratories, CardiNor, Novo Nordisk, Roche Diagnostics, and SpinChip Diagnostics. Dr deFilippi has received grant funding or contracts from NIH, Abbott Diagnostics, FujiRebio, Quidel:Ortho, Randox, Roche Diagnostics, Siemens Healthineers; has consulted or served on advisory Boards for Abbott Diagnostics, FujiRebio, Quidel:Ortho, and Roche Diagnostics; has performed endpoint adjudication for Siemens Healthineers, and Tosoh; has been a speaker for PathFast/PolyMedco, and Siemens Healthineers; and has been named a co-owner on a patent awarded to the University of Maryland (US Patent Application Number: 15/309,754) entitled: "Methods for Assessing Differential Risk for Developing Heart Failure." Dr Danesh serves on scientific advisory boards for AstraZeneca, Novartis, and UK Biobank; and has received multiple grants from academic, charitable and industry sources outside of the submitted work. Dr Danesh holds a British Heart Foundation Professorship and an NIHR Senior Investigator Award. Dr Wood is supported by the BHF Data Science Centre (HDRUK2023.0239), Health Data Research UK (Big Data for Complex Disease-HDR-23012), and as an NIHR Research Professor (NIHR303137). Dr Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Dr deLemos has received grant support from Abbott Diagnostics; has received consulting fees from Quidel Cardiovascular, Inc; has received honoraria for participation in endpoint committees from Beckman Coulter and Siemens Health Care Diagnostics; and has received fees for participation in Data Monitoring Committees from AstraZeneca, Novo Nordisk, Eli Lilly, Merck, Regeneron, Amgen, and Verve Therapeutics. Dr de Lemos has been named a co-owner on a patent awarded to the University of Maryland (US Patent Application Number: 15/309,754) entitled: "Methods for Assessing Differential Risk for Developing Heart Failure." Dr Pareek has been on the advisory boards of AstraZeneca, Janssen-Cilag, and Novo Nordisk; has received grant support from the Danish Cardiovascular Academy funded by the Novo Nordisk Foundation and the Danish Heart Foundation (grant number:

CPD5Y-2022004-HF) and the Danish Heart Foundation (grant number: 2024-12587); and has received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen-Cilag. Dr Welsh has received grant income from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics; and has received speaker fees from Novo Nordisk and Raisio. Dr Eggers has received consultancy fees from Roche Diagnostics. Dr Shah has received honoraria from Abbott Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Spencer J. Keene, Department of Public Health and Primary Care/Cardiovascular Epidemiology Unit, Victor Philip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Papworth Road, Cambridge CB2 0BB, United Kingdom. E-mail: sjk98@cam.ac.uk.

REFERENCES

1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. 2019;40(3):237-269.
2. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. *Nat Rev Cardiol*. 2017;14(8):472-483.
3. Shah ASV, Sandoval Y, Noaman A, et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. *BMJ*. 2017;359:j4788.
4. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. *J Am Coll Cardiol*. 2013;62(14):1242-1249.
5. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. *Clin Chem*. 2012;58(1):54-61.
6. Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. *J Am Coll Cardiol*. 2017;70(5):558-568.
7. Neumann JT, Twerenbold R, Weimann J, et al. Prognostic value of cardiovascular biomarkers in the population. *JAMA*. 2024;331(22):1898-1909.
8. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-3337.
9. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. *Circ Res*. 2012;110(5):658-662.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;74(10):e177-e232.
11. Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. *Eur Heart J*. 2016;37(30):2428-2437.
12. Welsh P, Kimenai DM, Shah ASV, et al. Multiple cardiac biomarkers to improve prediction of cardiovascular events: findings from the Generation Scotland Scottish Family Health Study. *Clin Chem*. 2024;70(2):403-413.
13. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol*. 2019;48(6), 1740-1740g.
14. Matsushita K, Jassal SK, Sang Y, et al. Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. *EclinicalMedicine*. 2020;27:100552.
15. Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol*. 2016;4(10):840-849.
16. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation*. 2011;123(13):1367-1376.
17. Welsh P, Hart C, Papacosta O, et al. Prediction of cardiovascular disease risk by cardiac biomarkers in 2 United Kingdom cohort studies: does utility depend on risk thresholds for treatment? *Hypertension*. 2016;67(2):309-315.
18. DeFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA*. 2010;304(22):2494-2502.
19. Seliger SL, Hong SN, Christenson RH, et al. High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). *Circulation*. 2017;135(16):1494-1505.
20. De Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010;304(22):2503-2512.
21. Welsh P, Preiss D, Hayward C, et al. Cardiac Troponin T and Troponin I in the general population. *Circulation*. 2019;139(24):2754-2764.
22. Welsh P, Preiss D, Shah ASV, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. *Clin Chem*. 2018;64(11):1607-1616.
23. Pareek M, Bhatt DL, Vaduganathan M, et al. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. *Eur J Prev Cardiol*. 2017;24(15):1648-1659.
24. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J*. 2012;33(18):2272-2281.
25. Thorsteinsdottir I, Aspelund T, Gudmundsson E, et al. High-sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the AGES-Reykjavik community-based cohort of older individuals. *Clin Chem*. 2016;62(4):623-630.
26. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. *Am Heart J*. 2013;166(3):541-548.
27. Lan NSR, Bell DA, McCaul KA, et al. High-sensitivity cardiac troponin I improves cardiovascular risk prediction in older men: HIMS (The Health in Men Study). *J Am Heart Assoc*. 2019;8(5):e011818.
28. Omland T, de Lemos JA, Holmen OL, et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. *Clin Chem*. 2015;61(4):646-656.
29. Eggers KM, Johnston N, Lind L, Venge P, Lindahl B. Cardiac troponin I levels in an elderly population from the community—the implications of sex. *Clin Biochem*. 2015;48(12):751-756.
30. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. *Clin Chem*. 2012;58(11):1574-1581.
31. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess*. 2003;7(27):1-173. iii-x.
32. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med*. 2015;162(1):55-63.
33. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J*. 2021;42(25):2439-2454.
34. Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the Fibrinogen Studies Collaboration. *Am J Epidemiol*. 2007;166(8):867-879.
35. Thompson S, Kaptoge S, White I, et al. Statistical methods for the time-to-event analysis of

- individual participant data from multiple epidemiological studies. *Int J Epidemiol*. 2010;39(5):1345-1359.
- 36.** Hageman SHJ, Dorresteijn JAN, Pennells L, et al. The relevance of competing risk adjustment in cardiovascular risk prediction models for clinical practice. *Eur J Prev Cardiol*. 2023;30(16):1741-1747.
- 37.** Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM, Emerging Risk Factors Collaboration. Assessing risk prediction models using individual participant data from multiple studies. *Am J Epidemiol*. 2014;179(5):621-632.
- 38.** Sanderson J, Thompson SG, White IR, Aspelund T, Pennells L. Derivation and assessment of risk prediction models using case-cohort data. *BMC Med Res Methodol*. 2013;13:113.
- 39.** Lopez E, Etxebarria-Elezgarai J, Amigo JM, Seifert A. The importance of choosing a proper validation strategy in predictive models. A tutorial with real examples. *Anal Chim Acta*. 2023;1275:341532.
- 40.** Pennells L, Kaptoge S, Wood A, et al. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. *Eur Heart J*. 2019;40(7):621-631.
- 41.** Sun L, Pennells L, Kaptoge S, et al. Polygenic risk scores in cardiovascular risk prediction: a cohort study and modelling analyses. *PLoS Med*. 2021;18(1):e1003498.
- 42.** Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016;388(10059):2532-2561.
- 43.** LaRocca G, Aspelund T, Greve AM, et al. Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study. *Eur Heart J*. 2017;38(46):3423-3430.
- 44.** IFCC. High Sensitivity Cardiac Troponin I and T Assay Analytical Characteristics Designated By Manufacturer v052023. 2023. Accessed May 23, 2024. <https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/>
- 45.** Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376(9753):1670-1681.
- 46.** Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380(9841):581-590.
- 47.** Shah AS, Newby DE, Mills NL. High-sensitivity troponin assays and the early rule-out of acute myocardial infarction. *Heart*. 2013;99(21):1549-1550.
- 48.** Lee KK, Noaman A, Vaswani A, et al. Prevalence, determinants, and clinical associations of high-sensitivity cardiac troponin in patients attending emergency departments. *Am J Med*. 2019;132(1), 110.e8-110.e21.
- 49.** Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*. 2017;357:j2099.
- 50.** Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT Equations. *Circulation*. 2024;149(6):430-449.
- 51.** Khan SS, Post WS, Guo X, et al. Coronary artery calcium score and polygenic risk score for the prediction of coronary heart disease events. *JAMA*. 2023;329(20):1768-1777.

KEY WORDS biomarkers, cardiac troponin, primary prevention, risk stratification

APPENDIX For supplemental text, figures, and tables, please see the online version of this paper.



Go to <http://www.acc.org/jacc-journals-cme> to take the CME/MOC/ECME quiz for this article.